Showing 7861-7870 of 8648 results for "".
- Lilly Begins Trial of Olumiant as Possible Coronavirus Treatmenthttps://modernod.com/news/lilly-begins-trial-of-olumiant-as-possible-coronavirus-treatment/2477899/Eli Lilly said Monday that the first patient has been enrolled in a phase 3 study testing its Incyte-partnered JAK1/JAK2 inhibitor Olumiant (baricitinib) in hospitalized adults with COVID-19. The trial, which will be conducted in
- Here Are the Specialties Hit Hardest by the COVID-19 Pandemichttps://modernod.com/news/here-are-the-specialties-hit-hardest-by-the-covid-19-pandemic/2479516/Health care revenue fell by nearly 50% in March and April for specialties that include primary care, oral surgery, dermatology and cardiology, a new study found, according to a FierceHealthcare
- Modernizing Medicine Introduces Modmed SynapSYS Development Platformhttps://modernod.com/news/modernizing-medicine-introduces-modmed-synapsys-development-platform/2479520/Modernizing Medicine has introduced modmed synapSYS, a new app development platform and suite of application programming interfaces (APIs). Modmed synapSYS was designed to allow third-party providers, healthcare institutions, and the developer community to easily interface Modernizing Medicine te
- Five Coronavirus Treatments In Developmenthttps://modernod.com/news/five-coronavirus-treatments-in-development/2479524/Right now, there is only one drug shown by rigorous scientific testing to be helpful for treating COVID-19. That drug is the antiviral medication called remdesivir, made by Gilead Sciences. But remdesivir’s proven benefits
- Study: Vision Loss Influences Perception of Soundhttps://modernod.com/news/study-vision-loss-influences-perception-of-sound/2477884/People with severe vision loss can less accurately judge the distance of nearby sounds, potentially putting them more at risk of injury, according to new research published in the journal Scientific Reports. Researchers from Anglia Ruskin University’s Vision and Eye Research Insti
- Oxford Biomedica Snags Manufacturing Equipment to Ramp Up Production of COVID-19 Vaccinehttps://modernod.com/news/oxford-biomedica-snags-manufacturing-equipment-to-ramp-up-production-of-covid-19-vaccine/2477880/In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca’s manufacturing partners has struck a deal for n
- Sherlock Bio Links With Danaher’s IDT to Supply its CRISPR-Based Coronavirus Testhttps://modernod.com/news/sherlock-bio-links-with-danahers-idt-to-supply-its-crispr-based-coronavirus-test/2477877/Sherlock Biosciences will team up with Danaher’s Integrated DNA Technologies division to scale up the manufacturing of its CRISPR-based coronavirus diagnostic test in the coming weeks, according to a FierceBiotech
- Novartis Provides Update On Use and Safety of Beovu (brolucizumab)https://modernod.com/news/novartis-provides-update-on-use-and-safety-of-beovu-brolucizumab/2477873/An internal review of post-marketing safety case reports of brolucizumab (Beovu; Novartis) has confirmed a rare occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion. Following FDA approval of Beovu in October 2019, Novartis rece
- Market Scope: Premium IOL Volume Faces Challenges in Rebounding Post-COVIDhttps://modernod.com/news/market-scope-premium-iol-volume-faces-challenges-in-rebounding-post-covid/2477871/Results from Part 1 of Market Scope’s “COVID-19 US Practice Impact Survey” reveal that nearly 41 percent of surgeons expect a decrease in premium IOL conversion once COVID-19 subsides. These surgeons expect an average decrease of 34 percent, and most respondents believe that financial
- SightGlass Vision Granted CE Mark for Eyeglasses That Slow Myopia Progression in Childrenhttps://modernod.com/news/sightglass-vision-granted-ce-mark-for-novel-eyeglasses-that-slow-myopia-progression-in-children/2477859/SightGlass Vision announced it has achieved CE Mark approval for its first product – novel eyeglasses designed to slow the progression of myopia in children. The approval allows the SightGlass Vision to commercialize its suite of Diffusion Optics Technology (DOT) products across the EU,